PubRank

M M Nau

Author PubWeight™ 71.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 p53: a frequent target for genetic abnormalities in lung cancer. Science 1989 7.51
2 Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1984 6.23
3 L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 1985 4.66
4 Differential expression of myc family genes during murine development. Nature 1986 3.57
5 Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990 2.97
6 p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992 2.90
7 p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992 2.64
8 Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999 2.32
9 Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001 2.30
10 Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 1985 2.12
11 Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A 1986 1.96
12 Immunoglobulin V/J recombination is accompanied by deletion of joining site and variable region segments. Proc Natl Acad Sci U S A 1980 1.72
13 Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992 1.72
14 Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992 1.63
15 Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 2001 1.50
16 myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 1987 1.43
17 Initiation of protein synthesis. 3. Factor-GTP-codon-dependent binding of F-met-tRNA to ribosomes. Proc Natl Acad Sci U S A 1967 1.42
18 cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 1999 1.29
19 Translation and translocation of defined RNA messengers. J Mol Biol 1969 1.27
20 Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001 1.26
21 Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992 1.19
22 Mutations in the p53 gene in primary human breast cancers. Cancer Res 1991 1.15
23 LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosomes Cancer 1997 1.14
24 cbl-3: a new mammalian cbl family protein. Oncogene 1999 1.13
25 Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. Curr Top Microbiol Immunol 1984 1.12
26 Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 1993 1.08
27 Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 2001 1.02
28 Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. Clin Cancer Res 2000 1.01
29 cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors. Mol Cell Biol Res Commun 1999 0.97
30 Translocation of mRNA codons. I. The preparation and characteristics of a homogeneous enzyme. Proc Natl Acad Sci U S A 1969 0.96
31 Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 2000 0.96
32 A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene 1993 0.92
33 Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res 1995 0.92
34 Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 1992 0.90
35 N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004 0.86
36 Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. Oncogene 1998 0.86
37 Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest 1992 0.85
38 Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines. Cancer Res 1986 0.79
39 Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harb Symp Quant Biol 1986 0.78
40 Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer. Princess Takamatsu Symp 1986 0.76
41 Differentiation stages of childhood acute lymphoblastic leukemias with p53 mutations. Leukemia 1994 0.75